Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingNot a traditional drug phaseinterventionalRules rewrite

Not a traditional drug phase: Quality-of-Life Assessment for Cervical Carcinoma

This early phase I trial compares the side effects between patients treated with proton radiation therapy versus intensity modulated radiation therapy after surgery for the treatment of endometrial or cervical cancer. Radiation therapy uses high energy protons or x-rays to kill tumor cells and shrink tumors.

Official registry: https://clinicaltrials.gov/study/NCT04567771 · Mayo Clinic · enrollment listed as 121

What this phase means

This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Quality-of-Life Assessment, Questionnaire Administration, or Radiation Therapy. The registry lists allocation as na. This early phase I trial compares the side effects between patients treated with proton radiation therapy versus intensity modulated radiation therapy after surgery for the treatment of endometrial or cervical cancer.

They plan to enroll about 121 people at 3 sites. Taking part typically means a procedure as part of the study plus check-ins.

Official title (unrewritten)

A Comparison of Acute Toxicities Between Patients Treated With Protons or Intensity-Modulated Radiation Therapy for Post-Operative Treatment of Endometrial or Cervical Cancers

Interventions: Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy

Primary outcome (registry wording): Change in Expanded Prostate Cancer Index Composite (EPIC) Bowel score

Who it is for (from inclusion criteria)

  • Ages 18 Years to any
  • Women only
  • Histologically confirmed diagnosis of cervical or endometrial cancer
  • Must have undergone an open or robotic hysterectomy (total abdominal, vaginal, radical, or total laparoscopic) for carcinoma of the cervix or endometrium
  • History and physical prior to registration
  • Documentation of history of:
  • Pelvic inflammatory disease
  • Planned to receive either proton or IMRT radiation treatment, with use of rectal balloon, at any Mayo Clinic site
  • Plan for RT to pelvis with or without para-aortic lymph node irradiation

Public study contact (from the registry)

Clinical Trials Referral Office

855-776-0015

mayocliniccancerstudies@mayo.edu

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

3 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phasePhoenix, Arizona
Not a traditional drug phase: Vaginal Fluid Collection for Endometrial Cancer

The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus (HR-HPV) detected in vaginal fluid and/or plasma. This proposal defines Phase II MDM-based cancer detection studies in endometrial cancer (EC) and endometrial hyperplasia with atypia (AEH) in vaginal fluid and 2) ovarian cancer (OC) in plasma and vaginal fluid.

NCT05051722 · Official ClinicalTrials.gov record · Mayo Clinic

RecruitingNot a traditional drug phaseChandler, Arizona
Not a traditional drug phase: Observational study, no intervention for Endometriosis

The goal of this watch-and-measure (no experimental treatment required) study is to determine the clinical validity of a deep neural network algorithm that utilizes protein biomarker detection of Endometriosis - "EndoCheck" - as an "aid in diagnosis" for endometriosis and to show validity as a diagnostic test

NCT05245695 · Official ClinicalTrials.gov record · Aspira Women's Health

RecruitingNot a traditional drug phaseDuarte, California
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

This is an watch-and-measure (no experimental treatment required) case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid.

NCT05366881 · Official ClinicalTrials.gov record · Adela, Inc

FAQ about this NCT record

Is NCT04567771 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT04567771?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT04567771?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary